Your search returned 6 studies. (Get alerts for new studies):
- A Trial of ZD6474 (Zactima), Paclitaxel, Carboplatin, 5-Fluorouracil, and XRT Followed by Surgery
Conditions: Cancer of the Esophagus, Gastroesophageal Junction or Stomach
1 Location available
- Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastro
Conditions: Adenocarcinoma of the Gastroesophageal Junction - Esophageal Cancer - Gastric Cancer
211 Locations available
- Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer
Conditions: Adenocarcinoma of the Esophagus - Adenocarcinoma of the Gastroesophageal Junction - Diffuse Adenocarcinoma of the Stomach - Intestinal Adenocarcinoma of the Stomach - Mixed Adenocarcinoma of the Stomach - Recurrent Esophageal Cancer - Recurrent Gastric Ca
1 Location available
- Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction
Conditions: Adenocarcinoma of the Esophagus - Adenocarcinoma of the Gastroesophageal Junction - Stage II Esophageal Cancer
1 Location available
- Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach
Conditions: Esophageal Cancer - Gastric Cancer
1 Location available
- Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy
Conditions: Adenocarcinoma of the Esophagus - Adenocarcinomas of the Gastroesophageal Junction - Recurrent Esophageal Cancer - Squamous Cell Carcinoma of the Esophagus - Stage IV Esophageal Cancer
1 Location available
|